Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Vimian Group AB ( (SE:VIMIAN) ).
Vimian Group AB has increased its total number of shares and votes following the issuance of new D, E1 2025, E2 2025 and E3 2025 shares under its LTIP 2025/2028 incentive programme and the conversion of a small number of C shares into ordinary shares. As of the last trading day in December 2025, the company has 529,262,637 shares outstanding, comprising several share classes with different voting rights, resulting in a total of 526,294,558.5 votes and reflecting ongoing use of equity-based incentives to align management and employees with shareholder interests while slightly diluting existing shareholders.
The most recent analyst rating on (SE:VIMIAN) stock is a Hold with a SEK39.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.
More about Vimian Group AB
Vimian Group AB is a Stockholm-headquartered global animal health company operating across Specialty Pharma, MedTech, Veterinary Services and Diagnostics. It aggregates pioneering and entrepreneurial businesses to provide innovative solutions to veterinary clinics and laboratories, reaching over 17,000 customers in more than 80 markets, with around 1,200 employees and annual revenues of approximately EUR 375 million.
Average Trading Volume: 297,636
Technical Sentiment Signal: Sell
Current Market Cap: SEK15.56B
For an in-depth examination of VIMIAN stock, go to TipRanks’ Overview page.